Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Goldman Sachs Physical Gold ETF (AAAU) vs Boston Scientific Corporation (BSX) Price & Performance

Goldman Sachs Physical Gold ETFTrade
Boston Scientific CorporationTrade

Price performance (Past 24H)

Key statistics

Goldman Sachs Physical Gold ETF vs Boston Scientific Corporation — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.51, while Boston Scientific Corporation trades at $51.55 (market cap $74.19B). The key difference: Goldman Sachs Physical Gold ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.

AAAUBSX
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$53.21$108.14
52-Week Low
$32.74$42.63
Market Cap
$74.19B
Enterprise Value
$86.27B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Goldman Sachs Physical Gold ETF

AAAU trades at $43.42, up 0.35% today, with a bullish technical signal from moving averages but bearish oscillators. Key support is at $42 and resistance at $44. Recent news highlights gold's strength amid cooling U.S. inflation and geopolitical tensions, with spot gold reaching $4,438/oz. Financial ratios are unavailable, limiting fundamental assessment.

The outlook for AAAU is supported by positive gold market dynamics, including central bank demand and inflation trends. Risks include potential Fed policy shifts and market volatility. Analyst sentiment is mixed, with technical indicators suggesting caution despite bullish momentum.

Boston Scientific Corporation

Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.

BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Goldman Sachs Physical Gold ETF

AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.

Read more on AAAU

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX